Field & Main Bank Sells 4,512 Shares of Pfizer Inc. (NYSE:PFE)

Field & Main Bank lowered its holdings in Pfizer Inc. (NYSE:PFE) by 40.7% during the 4th quarter, Holdings Channel reports. The firm owned 6,565 shares of the biopharmaceutical company’s stock after selling 4,512 shares during the period. Field & Main Bank’s holdings in Pfizer were worth $189,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in PFE. Charles Schwab Investment Management Inc. increased its holdings in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares during the last quarter. Morgan Stanley raised its holdings in shares of Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Pfizer by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after purchasing an additional 5,185,453 shares during the period. Invesco Ltd. lifted its stake in Pfizer by 30.9% in the third quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock valued at $797,901,000 after purchasing an additional 5,678,004 shares during the last quarter. Finally, California Public Employees Retirement System grew its holdings in Pfizer by 0.6% during the third quarter. California Public Employees Retirement System now owns 18,380,833 shares of the biopharmaceutical company’s stock valued at $609,692,000 after purchasing an additional 101,256 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE PFE traded up $0.25 on Monday, hitting $25.65. The stock had a trading volume of 41,630,566 shares, compared to its average volume of 41,999,020. The firm has a 50-day moving average of $26.92 and a 200-day moving average of $28.31. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The company has a market capitalization of $145.24 billion, a price-to-earnings ratio of 71.25, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.14 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.55%. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research note on Thursday, January 4th. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.